F
Fatima Chowdhry
Publications - 8
Citations - 123
Fatima Chowdhry is an academic researcher. The author has contributed to research in topics: Placebo-controlled study & Placebo. The author has an hindex of 5, co-authored 8 publications receiving 54 citations.
Papers
More filters
Journal ArticleDOI
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children
Azmi Nasser,Tesfaye Liranso,Toyin Adewole,Nicholas Fry,Joseph T. Hull,Fatima Chowdhry,Gregory D. Busse,Andrew J. Cutler,Nandita Joshi Jones,Robert L. Findling,Stefan Schwabe +10 more
TL;DR: SPN-812 significantly reduced ADHD symptoms in children and was well tolerated, suggesting that this drug may prove to be an effective treatment for children with ADHD.
Journal ArticleDOI
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
Azmi Nasser,Tesfaye Liranso,Toyin Adewole,Nicholas Fry,Joseph T. Hull,Fatima Chowdhry,Gregory D. Busse,Zare Melyan,Andrew J. Cutler,Robert L. Findling,Stefan Schwabe +10 more
TL;DR: In this article, the authors evaluated the efficacy and tolerability of SPN-812-200 and 400-mg once daily in children 6-11 years of age with ADHD.
Journal ArticleDOI
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Azmi Nasser,Tesfaye Liranso,Toyin Adewole,Nicholas Fry,Joseph T. Hull,Gregory D. Busse,Fatima Chowdhry,Andrew J. Cutler,Nandita Joshi Jones,Robert L. Findling,Stefan Schwabe +10 more
TL;DR: In this article, the authors evaluated the efficacy and safety of Viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in adolescents.
Journal Article
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
Azmi Nasser,Tesfaye Liranso,Toyin Adewole,Nicholas Fry,Joseph T. Hull,Fatima Chowdhry,Gregory D. Busse,Zare Melyan,Andrew J. Cutler,Robert L. Findling,Stefan Schwabe +10 more
TL;DR: The SPN-812 was well tolerated at both doses, with <5% discontinuation rate due to adverse events as discussed by the authors, and significant improvements were observed on a number of secondary endpoints, including change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) total score.
Journal ArticleDOI
113 Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303) Assessing Efficacy and Safety of Extended-Release Viloxazine in Children with ADHD.
TL;DR: SPN-812 met the primary objective for both the 200 and 400 mg doses and the key secondary objective (CGI-I) for both those doses with statistical significance in this Phase 3, randomized, double-blind study in children ages 6-11yrs with ADHD.